Therapeutic Effects of Pegylated-interferon-α2a in a Mouse Model of Multiple Sclerosis

Overview

Journal Cent Eur J Immunol

Publisher Termedia

Specialty Allergy & Immunology

Date 2018 May 8

PMID 29731688

Citations 2

Authors

Sanaz Afraei

Reza Sedaghat

Farzaneh Tofighi Zavareh

Zahra Aghazadeh

Parvin Ekhtiari

Gholamreza Azizi

Abbas Mirshafiey

Affiliations

Soon will be listed here.

Abstract

Introduction: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). EAE is mainly mediated by adaptive and innate immune responses that lead to an inflammatory demyelination and axonal damage. The aim of the present research was to examine the therapeutic efficacy of Peg interferon alpha 2a (Peg-IFN α-2a) as a serine protease inhibitor on EAE model.

Material And Methods: EAE induction was performed in female C57BL/6 mice by myelin oligodendrocyte glycoprotein (35-55) (MOG) in Complete Freund's Adjuvant (CFA) emulsion, and Peg-IFN α-2a was used for the treatment of EAE. During the course of the study, clinical evaluation was assessed, and on day 21 post-immunisation blood samples were taken from the heart of mice for evaluation of IL-6, and enzymatic and non-enzymatic antioxidants. The mice were sacrificed and the brains and cerebellums were removed for histological analysis.

Results: Our findings indicated that Peg-IFN α-2a had beneficial effects on EAE by attenuation of the severity and a delay in the onset of disease. Histological analysis showed that treatment with Peg-IFN α-2a can reduce inflammation criteria. Moreover, in Peg-IFN α-2a-treated mice the serum level of IL-6 was significantly less than in controls, and total antioxidant capacity was significantly more than in the control animals.

Conclusions: These data indicate that Peg-IFN α-2a as an anti-serine protease with immunomodulatory properties may be useful for the treatment of MS.

Citing Articles

The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases.

Zeng L, Xiang W, Xiao W, Wu Y, Sun L MedComm (2020). 2025; 6(3):e70101.

PMID: 40060194 PMC: 11885892. DOI: 10.1002/mco2.70101.

The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.

Hui B, Zhi L, Retinasamy T, Arulsamy A, Law C, Shaikh M J Alzheimers Dis. 2023; 94(s1):S45-S66.

PMID: 36776068 PMC: 10473139. DOI: 10.3233/JAD-221081.

The Brain Entangled: The Contribution of Neutrophil Extracellular Traps to the Diseases of the Central Nervous System.

Manda-Handzlik A, Demkow U Cells. 2019; 8(12).

PMID: 31766346 PMC: 6953104. DOI: 10.3390/cells8121477.

References

Azizi G, Navabi S, Al-Shukaili A, Seyedzadeh M, Yazdani R, Mirshafiey A . The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease. Sultan Qaboos Univ Med J. 2015; 15(3):e305-16. PMC: 4554263. DOI: 10.18295/squmj.2015.15.03.002. View

Ferretti G, Bacchetti T . Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci. 2011; 311(1-2):92-7. DOI: 10.1016/j.jns.2011.09.004. View

Beck J, Rondot P, CATINOT L, FALCOFF E, Kirchner H, Wietzerbin J . Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. Acta Neurol Scand. 1988; 78(4):318-23. DOI: 10.1111/j.1600-0404.1988.tb03663.x. View

Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S . IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008; 105(26):9041-6. PMC: 2449361. DOI: 10.1073/pnas.0802218105. View

Maimone D, Gregory S, Arnason B, Reder A . Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991; 32(1):67-74. DOI: 10.1016/0165-5728(91)90073-g. View

Deponte M . Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta. 2012; 1830(5):3217-66. DOI: 10.1016/j.bbagen.2012.09.018. View

Mirshafiey A, Asghari B, Ghalamfarsa G, Jadidi-Niaragh F, Azizi G . The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis. Sultan Qaboos Univ Med J. 2014; 14(1):e13-25. PMC: 3916267. DOI: 10.12816/0003332. View

Heliovaara M, Knekt P, Aho K, Aaran R, Alfthan G, Aromaa A . Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis. 1994; 53(1):51-3. PMC: 1005243. DOI: 10.1136/ard.53.1.51. View

Haider L, Fischer M, Frischer J, Bauer J, Hoftberger R, Botond G . Oxidative damage in multiple sclerosis lesions. Brain. 2011; 134(Pt 7):1914-24. PMC: 3122372. DOI: 10.1093/brain/awr128. View

10.

Taysi S, Polat F, Gul M, Sari R, Bakan E . Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int. 2002; 21(5):200-4. DOI: 10.1007/s00296-001-0163-x. View

11.

Shahbazi M, Ebadi H, Fathi D, Roshandel D, Mohamadhosseni M, Tahmasebi A . HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population. Mult Scler. 2010; 16(10):1173-7. DOI: 10.1177/1352458510376177. View

12.

Azizi G, Haidari M, Khorramizadeh M, Naddafi F, Sadria R, Hassan Javanbakht M . Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iran J Allergy Asthma Immunol. 2014; 13(3):198-206. View

13.

Azizi G, Goudarzvand M, Afraei S, Sedaghat R, Mirshafiey A . Therapeutic effects of dasatinib in mouse model of multiple sclerosis. Immunopharmacol Immunotoxicol. 2015; 37(3):287-94. DOI: 10.3109/08923973.2015.1028074. View

14.

Reddy K . Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000; 34(7-8):915-23. DOI: 10.1345/aph.10054. View

15.

Strader D, Wright T, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. DOI: 10.1002/hep.20119. View

16.

Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H . Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002; 8(5):500-8. DOI: 10.1038/nm0502-500. View

17.

Love S . Demyelinating diseases. J Clin Pathol. 2006; 59(11):1151-9. PMC: 1860500. DOI: 10.1136/jcp.2005.031195. View

18.

Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney Jr D . Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421(6924):756-60. DOI: 10.1038/nature01392. View

19.

Langrish C, Chen Y, Blumenschein W, Mattson J, Basham B, Sedgwick J . IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201(2):233-40. PMC: 2212798. DOI: 10.1084/jem.20041257. View

20.

Davitashvili D, Beridze M, Shakarishvili R, Kiziria M, Sanikidze T . The role of endogenous antiradical protective system in multiple sclerosis. Georgian Med News. 2012; (205):11-9. View